Lentigo Maligna: Mohs Surgery vs. Imiquimod Cream - How to Choose

What Is Lentigo Maligna

Lentigo maligna is a form of melanoma in situ. The cancer cells are confined to the epidermis, the outermost layer of the skin, and have not yet invaded deeper tissue. The lesion appears as a slowly enlarging, irregularly pigmented patch on chronically sun-damaged skin, most often on the face of older adults. It accounts for between 4 and 15 percent of all melanomas and is the most common form of melanoma in situ.

When melanoma cells from a lentigo maligna break through to the dermis, the lesion becomes lentigo maligna melanoma (LMM). At that point it is no longer in situ and follows the surgical and staging guidelines for invasive melanoma. The article below focuses on lentigo maligna while it is still confined to the epidermis.

“Lentigo maligna is one of the trickiest tumors in dermatology because it spreads invisibly through sun-damaged skin around the visible spot. The choice between surgery and topical cream is rarely simple. For most patients with operable lesions, margin-controlled surgery gives the best long-term outcome. For older patients with very large facial lesions or significant comorbidities, imiquimod is a reasonable option to discuss.”

Why Treatment Matters

Lentigo maligna grows slowly, but it does progress. Pooled data suggest the annual risk of conversion to invasive melanoma is approximately 3.5 percent. The risk is not constant. It rises sharply with lesion size, and lesions larger than 4 cm have a high probability of harboring an invasive focus that may not be visible clinically. For this reason, lentigo maligna is treated rather than observed in the vast majority of cases.

The goal of treatment is complete clearance of all atypical melanocytes from the epidermis. Two general strategies achieve this: surgical removal with margin control, or topical immunotherapy with imiquimod cream. They are not equivalent.

The Subclinical Extension Problem

The central challenge in treating lentigo maligna is that the visible pigmented patch usually represents only the tip of an iceberg. Atypical melanocytes spread through the epidermis well beyond what is visible to the naked eye, sometimes by a centimeter or more.

Studies of surgical margins illustrate this clearly. A 6 mm margin around the clinical edge clears only about 60-79 percent of cases. A 9 mm margin clears around 72 percent. A 12 mm margin clears around 91 percent. Even an 18 mm margin clears only about 97 percent of head and neck lesions. This is why a single fixed-margin excision often fails to capture all the cancer cells.

This subclinical extension is the reason margin-controlled surgical techniques and reflectance confocal microscopy mapping have become preferred over standard wide local excision for facial lentigo maligna.

Surgical Treatment: Mohs and Staged Excision

Margin-controlled surgical removal is the most effective treatment for lentigo maligna. Several variations exist, and the recurrence rates vary by technique.

Mohs Surgery with MART-1 Immunostaining

This is the most accurate option in published data. The lesion is removed in stages, and each layer is processed and stained with MART-1 (also called Melan-A), an immunohistochemical stain that highlights melanocytes. The Mohs surgeon examines the slides during the procedure and removes additional tissue only where atypical cells remain. A 2023 meta-analysis of more than 6,000 cases reported a recurrence rate of less than 1 percent with this approach.

The limitation is technical. Standard frozen sections without immunostaining make individual melanocytes difficult to interpret because freezing causes artifactual changes in nuclear appearance. Adding MART-1 solves this, but it requires laboratory infrastructure and trained staff. Surveys suggest that only about 22 percent of Mohs surgeons currently use immunostaining routinely for lentigo maligna.

Slow Mohs and Staged Excision

When MART-1 frozen sections are not available, two related techniques are used. "Slow Mohs" sends each margin for paraffin-embedded permanent sections, which are read over 1-2 days while the patient waits with a temporary dressing. Staged excision (sometimes called the square procedure or Johnson technique) is similar but uses a different geometric approach to mapping the margins.

Both approaches achieve recurrence rates in the 1-6 percent range across published series, lower than wide local excision but slightly higher than Mohs with MART-1.

Standard Wide Local Excision

A traditional wide local excision with 5-10 mm fixed margins can be effective for small, well-defined lentigo maligna lesions. However, pooled meta-analysis data show a recurrence rate of approximately 13 percent. The higher recurrence reflects subclinical extension that escapes detection without complete margin assessment.

For a related comparison of Mohs versus standard excision in non-melanoma skin cancer, see our article on Mohs surgery versus standard excision.

Imiquimod Cream: When and Why

Imiquimod 5% cream is a topical immunomodulator that activates the local immune response against tumor cells. It is FDA-approved for actinic keratosis and superficial basal cell carcinoma, and is used off-label for lentigo maligna in selected situations.

How It Is Used

A typical regimen involves applying the cream once daily, five to seven times per week, for approximately 12 weeks. Outcomes are best in patients who complete more than five applications per week and at least 60 total applications. The cream causes inflammation, redness, crusting, and sometimes ulceration at the treated site, which is part of the expected immune response.

What the Evidence Shows

A 2023 systematic review pooling data from 87 studies and 1,803 lesions reported a complete clearance rate of approximately 63 percent. Earlier reviews reported clearance rates as high as 76-78 percent, though those numbers include studies with shorter follow-up. Among lesions that initially clear, the relapse rate is approximately 9-10 percent in mid-term follow-up, and rises to as much as 20 percent in studies with follow-up beyond four years.

In other words, imiquimod is reasonably effective in the short term but has lower long-term cure rates than margin-controlled surgery.

When Imiquimod Is Considered

The American Academy of Dermatology and NCCN guidelines reserve imiquimod for situations where surgery is impractical or contraindicated. These include:

Imiquimod is not recommended as first-line treatment for lesions that can be surgically removed. The evidence consistently shows that surgery has lower recurrence rates and better long-term outcomes.

Comparing the Two Approaches

For most patients with operable lentigo maligna, the discussion is between margin-controlled surgery (preferred) and imiquimod (reserved). The key differences:

Cure rate. Surgery with appropriate margin control achieves recurrence rates between less than 1 percent and 6 percent depending on technique. Imiquimod achieves complete clearance in roughly 60-78 percent of patients, with 9-20 percent relapse among those who initially clear.

Tissue impact. Surgery removes tissue and leaves a defined wound that requires reconstruction or healing. Imiquimod preserves tissue but causes a prolonged inflammatory reaction during treatment.

Time commitment. Surgery is a single procedure with a defined recovery period. Imiquimod requires daily home application for 12 weeks plus follow-up.

Verification of clearance. After surgery, the pathology report confirms whether margins are clear. After imiquimod, post-treatment biopsies are needed and may not capture residual disease in untested areas.

Suitability. Surgery is appropriate for most operable lesions. Imiquimod is appropriate when surgery is not.

Follow-Up After Treatment

Regardless of treatment method, lentigo maligna requires long-term surveillance. Recurrences can appear years or even decades after apparent clearance, particularly in adjacent sun-damaged skin. Standard follow-up includes a full-body skin examination every 6-12 months for the first 1-2 years, then annually for life.

For more on what surveillance looks like after a skin cancer diagnosis, see our article on follow-up after skin cancer.

Special Considerations in Israel

Lentigo maligna is particularly relevant for the Israeli population for several reasons. Decades of cumulative UV exposure on the face, common in patients aged 60 and older who grew up before sun protection became standard, are exactly the conditions in which lentigo maligna develops. Israel has one of the highest melanoma incidence rates globally, including melanoma in situ.

Most cases are diagnosed by dermatologists during routine skin checks. Once a biopsy confirms the diagnosis, the next step is referral to a Mohs surgeon or surgical dermatologist with experience in margin-controlled techniques for melanoma in situ. Coverage through the Israeli health basket varies by location and case complexity. For details on Mohs coverage in Israel, see our insurance and Mohs surgery guide.

Frequently Asked Questions

Is lentigo maligna the same as melanoma?

Lentigo maligna is melanoma in situ. The cancer cells are confined to the epidermis and have not invaded deeper layers. When they do invade, the lesion becomes lentigo maligna melanoma (LMM), which is invasive melanoma and follows different treatment guidelines including possible sentinel lymph node biopsy.

Why is lentigo maligna so hard to treat?

The atypical melanocytes spread silently through sun-damaged skin well beyond the visible patch. Studies show that fixed-margin excision often misses cells extending centimeters beyond the clinical border. This is why margin-controlled techniques have become preferred for facial lentigo maligna.

Can imiquimod cream completely cure lentigo maligna?

Imiquimod achieves complete clearance in approximately 60-78 percent of cases in published data. About 9-20 percent of cleared lesions recur during long-term follow-up. Cure rates are lower than with margin-controlled surgery, which is why guidelines reserve imiquimod for patients who cannot or should not undergo surgery.

How long does Mohs surgery take for lentigo maligna?

Mohs surgery with MART-1 immunostaining can take longer than standard Mohs because each layer requires staining and interpretation. A typical case may extend over a full day, sometimes split across two days for complex lesions. "Slow Mohs" with paraffin sections often requires the patient to return one or two days after the initial excision for results and reconstruction.

What does the scar look like after lentigo maligna surgery?

The size and appearance of the scar depend on the lesion size, location, and reconstruction technique. Small lesions can be closed in a line. Larger lesions may require local flaps or skin grafts. Because lentigo maligna typically occurs on the face, reconstruction is performed with attention to facial aesthetic units to preserve appearance.

Will I need follow-up after treatment?

Yes. Long-term follow-up is essential. Recurrences can appear years after treatment, and patients with one lentigo maligna are at higher risk for additional skin cancers. Annual skin examinations for life are recommended, with more frequent visits during the first 1-2 years.